Tom 7, Nr 4 (2022)
Praca badawcza (oryginalna)
Opublikowany online: 2022-04-25

dostęp otwarty

Wyświetlenia strony 3486
Wyświetlenia/pobrania artykułu 82
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

The influence of surgery quality on the longtime results of gastric cancer combination therapy

Ireneusz Pierzankowski1, Adam Dmitruk1, Sebastian Rybski2, Lucjan Wyrwicz3, Tomasz Olesiński1
Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory 2022;7(4):258-264.

Streszczenie

Introduction.The aim of this study was to analyze the influence of surgical center experience on the long term survival of patients with locoregionally advanced gastric adenocarcinoma undergoing primary surgery, followed by comple­mentary chemoradiotherapy according to MacDonald regimen.

Material and methods.154 patients treated surgically, including 75 (48.7%) at the Maria Sklodowska-Curie National Research Institute of Oncology (NIO-PIB) in Warsaw, and 79 (51.3%) outside this center. Both groups were retrospectively analyzed. The compared groups were statistically homogeneous. The following parameters were analyzed: age, gender, tumor differentiation, TNM VII (2010) staging, nodal index, radicality of surgical treatment, tumor type according to the Lauren classification, clinical stage, presence of prognostic factors, overall survival time.

Results.Among those patients operated on at NIO-PIB, 71 (94.7%) patients underwent radical resection, 4 (5.3%) cases were microscopically non-radical resection had. There were no macroscopically non-radical resections (0%). For patients operated on outside NIO-PIB, 60 (75.9%) R0 resections, 15 (19%) R1 resections and 4 (5.1%) R2 resections were performed. The percentage of radical resections was significantly higher at NIO-PIB (p = 0.001). In 77% of patients operated on at NIO-PIB, disease progression in terms of feature could be established. This percentage for patients operated on outside the NIO-PIB was 54% and was significantly lower (p = 0.001). The probability of 5-year survival was 41.6% in total, with 45.3% for the group of patients operated on in the NIO-PIB and 38.0% for the group of patients operated on outside the NIO-PIB, respectively (p = 0.628).

Conclusions.The quality of surgical treatment was significantly higher in NIO-PIB. The difference in 5-year overall survival (OS) between the compared groups is not statistically significant. Complementary treatment with chemoradiotherapy (CRT) according to MacDonald regimen reduces the shortcomings in the quality of surgical treatment in locoregionally advanced gastric adenocarcinoma.  

Artykuł dostępny w formacie PDF

Pokaż PDF (angielski) Pobierz plik PDF

Referencje

  1. National Cancer Registry. http://onkologia.org.pl/nowotwory-zoładka.
  2. Al-Batran SE, Hofheinz RD, Pauligk CI, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol. 2016; 17(12): 1697–1708.
  3. Olesiński T. Surgical treatment of gastric cancer: then and now. Nowotwory. Journal of Oncology. 2017; 66(5): 408–414.
  4. Smyth EC, Verheij M, Allum W, et al. ESMO Guidelines Committee. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016; 27(suppl 5): v38–v49.
  5. MacDonald JS, Smalley SR, Benedetti JI, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastrooesophagal junction. N Engl J Med. 2001; 345(10): 725–730.
  6. Chelakkot PG, Ravind R, Sruthi K, et al. Treatment in resectable non-metastatic adenocarcinoma of stomach: Changing paradigms. Indian J Cancer. 2019; 56(1): 74–80.
  7. Xu J, Zhu J, Wei Q. Adjuvant Radiochemotherapy versus Chemotherapy Alone for Gastric Cancer: Implications for Target Definition. J Cancer. 2019; 10(2): 458–466.
  8. Aoyama T, Yoshikawa T. Adjuvant therapy for locally advanced gastric cancer. Surg Today. 2017; 47(11): 1295–1302.
  9. Zhou MLZ, Yang W, Wang YQI, et al. Adjuvant chemoreadiotherapy versus adjuvant chemotherapy for patients with N3 gastric cancer after D2/R0 resection: a retrospective study based on propen sity score analyses. Cancer ManagRes. 2019: 4855–4870.
  10. Zhou ML, Kang M, Li GC, et al. Postoperative chemoradiotherapy versus chemotherapy for R0 resected gastric cancer with D2 lymph node dissection: an up-to-date meta-analysis. World J Surg Oncol. 2016; 14(1): 209.
  11. Xu J, Zhu J, Wei Q. Adjuvant Radiochemotherapy versus Chemotherapy Alone for Gastric Cancer: Implications for Target Definition. J Cancer. 2019; 10(2): 458–466.
  12. Cats A, Jansen EPM, van Grieken NCT, et al. Chemotherapy versus chemioradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer ( CRITICS):an international, open – label, randomized phase 3 trial. Lancer oncol. 2018; 19(5): 616–628.
  13. Leong T, Smithers B, Haustermans K, et al. TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG. Ann Surg Oncol. 2017; 24(8): 2252–2258.
  14. Slagter AS, Jansen EPM, van La, et al. CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer. BMC Cancer. 2018; 18: 877.
  15. Kanhere H, Goel R, Finlay B, et al. Radical Gastrectomy: Still the Cornerstone of Curative Treatment for Gastric Cancer in the Perioperative Chemotherapy Era-A Single Institute Experience over a Decade. Int J Surg Oncol. 2018; 2018: 9371492.
  16. Nakamura Y, Yamanaka T, Chin K, et al. Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 Gastrectomy. Ann Surg Oncol. 2019; 26(2): 465–472.
  17. Yuan P, Wu Z, Li Z, et al. Impact of postoperative major complications on long-term survival after radical resection of gastric cancer. BMC Cancer. 2019; 19(1): 833.
  18. Datta J, McMillan MT, Ecker BL, et al. Implications of Lymph Node Staging on Selection of Adjuvant Therapy for Gastric Cancer in the United States: A Propensity Score-matched Analysis. Ann Surg. 2016; 263(2): 298–305.
  19. Stiekema J, Trip AK, Jansen EPM, et al. Does adjuvant chemoradiotherapy improve the prognosis of gastric cancer after an r1 resection? Results from a dutch cohort study. Ann Surg Oncol. 2015; 22(2): 581–588.
  20. Claassen YHM, de Steur WO, Hartgrink HH, et al. Surgicopathological Quality Control and Protocol Adherence to Lymphadenectomy in the CRITICS Gastric Cancer Trial. Ann Surg. 2018; 268(6): 1008–1013.
  21. Claassen YHM, Hartgrink HH, de Steur WO, et al. Impact of upfront randomization for postoperative treatment on quality of surgery in the CRITICS gastric cancer trial. Gastric Cancer. 2019; 22(2): 369–376.
  22. Claassen YHM, van Amelsfoort RM, Hartgrink HH, et al. Effect of Hospital Volume With Respect to Performing Gastric Cancer Resection on Recurrence and Survival: Results From the CRITICS Trial. Ann Surg. 2019; 270(6): 1096–1102.



Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory